Targeted protein degradation (TPD) is an emerging therapeutic modality with the potential to
tackle disease-causing proteins that have historically been highly challenging to target with …

During the coronavirus disease 2019 (COVID-19) pandemic, a wave of rapid and
collaborative drug discovery efforts took place in academia and industry, culminating in …

Severe COVID-19 is characterized by persistent lung inflammation, inflammatory cytokine
production, viral RNA and a sustained interferon (IFN) response, all of which are …

Abstract Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the causative
agent of the pandemic disease COVID-19, which is so far without efficacious treatment. The …

Molnupiravir is an orally available antiviral drug candidate currently in phase III trials for the
treatment of patients with COVID-19. Molnupiravir increases the frequency of viral RNA …

The SARS-CoV-2 pandemic and its unprecedented global societal and economic disruptive
impact has marked the third zoonotic introduction of a highly pathogenic coronavirus into the …

The pandemic of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
has been posing great threats to the world in many aspects. Effective therapeutic and …

Abstract Coronavirus disease 2019 (COVID-19), caused by a strain of coronavirus known as
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging virus that is
highly pathogenic and has caused the recent worldwide pandemic officially named …

SARS-CoV-2 is an extremely contagious respiratory virus causing adult atypical pneumonia
COVID-19 with severe acute respiratory syndrome (SARS). SARS-CoV-2 has a single …